Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its third quarter revenues skyrocketed 300 percent year over year due to growth in the firm's DecisionDx- Melanoma test report volume.

For the three months ended Sept. 30, the skin cancer test developer reported total revenues of $14.8 million, up from $3.7 million during the same period a year earlier and beating analysts' average estimate of $9.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.